Browse by Poster Presenter

Skip to main content

CTOS 2025 Main banner

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

E
Easton, Rachael

Cogent Biosciences
(P 425) BEZUCLASTINIB EXPANDED ACCESS PROGRAM (EAP) FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST)
Rachael Easton
Favorite
Ebb, David

Massachusetts General Hospital
(P 290) CLINICAL OUTCOMES AFTER RADIOTHERAPY FOR PATIENTS WITH POORLY DIFFERENTIATED CHORDOMA
David Ebb
Favorite
Echebarria-Barona, Aizpea

Hospital Universitario Cruces
(P 71) GERMLINE POLYMORPHISMS IN THE VEGF PATHWAY AS PROGNOSTIC BIOMARKERS IN LOCALIZED HIGH-GRADE OSTEOSARCOMA: A STUDY BASED ON DATA FROM THE GEIS-33 PROTOCOL
Aizpea Echebarria-Barona
Favorite
Echeverri, Claudia

Fundación Colombiana de Cancerología Clínica Vida
(P 219) RETROPERITONEAL SARCOMA: HEALTH SYSTEM BARRIERS AND THE RATIONALE FOR A SPECIALIZED SARCOMA UNIT
Claudia Echeverri
Favorite
(P 301) RETROPERITONEAL SARCOMA: SINGLE CENTER EXPERIENCE IN LATIN AMERICA. DO WE HAVE DIFFERENT SARCOMAS WHEN COMPARED TO THE REST OF THE WORLD?
Claudia Echeverri
Favorite
Eckhoff, Michael

Texas Tech University
(P 84) A MULTICENTER COMPARISON OF REVERSE TOTAL SHOULDER ARTHROPLASTY VERSUS HEMIARTHROPLASTY FOR ENDOPROSTHETIC RECONSTRUCTION FOLLOWING ONCOLOGIC RESECTION OF THE PROXIMAL HUMERUS
Michael Eckhoff
Favorite
Eden, Amir

Department of Genetics, The Hebrew University of Jerusalem, Jerusalem, Israel.
(P 06) RAPID, POINT-OF-CARE DNA METHYLATION & MOLECULAR LANDSCAPE BASED SARCOMA CLASSIFICATION
Amir Eden
Favorite
Ednie, Alexander

Nova Scotia Health Authority
(P 143) IMPACT OF SURGICAL MARGINS IN CHEST WALL CHONDROSARCOMAS: A CANSARCC STUDY
Alexander Ednie
Favorite
Eeles, Christopher

Princess Margaret Cancer Centre, University Health Network
(P 68) MULTI-OMIC INTRA- AND INTER-TUMOR HETEROGENEITY OF BENIGN SMOOTH MUSCLE TUMORS
Christopher Eeles
Favorite
Eghtedari, Cyrus

Case Western Reserve University School of Medicine
(P 457) A RETROSPECTIVE REVIEW OF LOW-GRADE FIBROMYXOID SARCOMA: SURGICAL MANAGEMENT, RADIATION THERAPY, AND OUTCOMES
Cyrus Eghtedari
Favorite
Eguchi, Shiori

New York Medical College
(P 76) CD47 BLOCKADE SYNERGIZES WITH CHEMOTHERAPY IN ENHANCING MACROPHAGE PHAGOCYTOSIS OF EWING SARCOMA CELLS
Shiori Eguchi
Favorite
Eich, Anna

Sarcoma Unit, Department of Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University
(P 441) COLOSARC-Q: A PROSPECTIVE MULTICENTER STUDY FOR EVALUATING SURGICAL STRATEGIES FOR COLORECTAL RESECTIONS AND POSTOPERATIVE QUALITY OF LIFE IN RETROPERITONEAL SARCOMA PATIENTS
Anna Eich
Favorite
Ekert, Paul

Children's Cancer Institute
(P 11) ESTABLISHMENT, CHARACTERIZATION AND RESEARCH APPLICATION OF EIGHT NOVEL PATIENT-DERIVED OSTEOSARCOMA CELL LINES
Paul Ekert
Favorite
(P 266) TARGETING THE DNA DAMAGE RESPONSE TO ADVANCE PRECISION THERAPIES IN PAEDIATRIC SARCOMA
Paul Ekert
Favorite
Eldershaw, Ruth

Department of Work and Pensions
(P 207) LONG-TERM FOLLOW-UP AND LATE EFECTS MONITORING FOR UK BONE SARCOMA PATIENTS: A SERVICE MAPPING EXCERCISE
Ruth Eldershaw
Favorite
Elias, Anthony

University of Colorado School of Medicine
(P 234) DOXORUBICIN PLUS BOTENSILIMAB, A NEXT GENERATION CTLA4 INHIBITOR, WITH OR WITHOUT BALSTILIMAB, A PD1 INHIBITOR, IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMAS
Anthony Elias
Favorite
Elliott, Andrew

Caris Life Sciences
(P 154) BCOR-MUTATED CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMA: A CLINICOPATHOLOGIC STUDY
Andrew Elliott
Favorite
Elliott, Leighton

University of Florida
(P 44) A SYSTEMATIC REVIEW OF FUSION-DRIVEN SARCOMAS
Leighton Elliott
Favorite
(P 129) HIJACKED FUEL: GLYCOGEN-DRIVEN METABOLIC SHIFTS IN IDH1-MUTANT CHONDROSARCOMA
Leighton Elliott
Favorite
(P 248) AN EX VIVO ASSAY TO PREDICT IMMUNOTHERAPY RESPONSE IN SARCOMA
Leighton Elliott
Favorite
(P 275) NEXT GENERATION SEQUENCING IN ADOLESCENT AND YOUNG ADULT (AYA) SARCOMAS: CLINICAL IMPACT, DIAGNOSTIC UTILITY, AND IMPLICATIONS
Leighton Elliott
Favorite
(P 325) FUSION GENES IN SARCOMAS: DIAGNOSTIC APPROACHES AND EMERGING TARGETED THERAPIES
Leighton Elliott
Favorite
(P 401) LONG-TERM OUTCOMES OF IMATINIB-TREATED DERMATOFIBROSARCOMA PROTUBERANS: INSIGHTS FROM A SINGLE-INSTITUTION CASE SERIES
Leighton Elliott
Favorite
ElSenduny, Fardous

Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
(P 462) HDAC INHIBITORS AS POTENTIAL SFT THERAPIES
Fardous ElSenduny
Favorite
Emanuela, Palmerini

University of Miami
(P 117) THERAPEUTIC POTENTIAL OF DOXORUBICIN AND DASATINIB COMBINATION IN OSTEOSARCOMA
Palmerini Emanuela
Favorite
(P 131) GLUCOSE TRANSPORTER 1 (GLUT1) INHIBITION DECREASES THE GROWTH AND PROLIFERATION OF CHONDROSARCOMA
Palmerini Emanuela
Favorite
(P 225) GLOBAL REGISTRY OF SOLITARY FIBROUS TUMORS (SFT): INTEGRATING CLINICAL, MOLECULAR, AND ENVIRONMENTAL DATA- THE HOROWITZ SFT INITIATIVE (HSFTI)
Palmerini Emanuela
Favorite
(P 369) CLINICAL CHARACTERISTICS & TREATMENT OUTCOME PATTERNS OF SOLITARY FIBROUS TUMORS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS
Palmerini Emanuela
Favorite
Endo, Makoto

Kyushu University
(P 128) ISOCITRATE DEHYDROGENASE 1 (IDH1) MUTATION TESTING IN THE PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA (CHONQUER)
Makoto Endo
Favorite
(P 472) LANDSCAPE OF ULTRA-RARE SARCOMAS: A NATIONWIDE STUDY FOR EPIDEMIOLOGY AND PROGNOSIS
Makoto Endo
Favorite
Engelholm, Lars Henning

Finsen Laboratory, Biotech Research and Innovation Centre, University of Copenhagen
(P 36) MODULATION OF THE SARCOMA MICROENVIRONMENT THROUGH β-ADRENERGIC BLOCKADE
Lars Henning Engelholm
Favorite
Engelmann, Bodil Elisabeth

Department of Oncology, Herlev University Hospital
(P 05) CONCORDANCE OF GENOMIC ALTERATIONS WITH CIRCULATING TUMOR DNA: INITIAL FINDINGS FROM A PILOT STUDY
Bodil Elisabeth Engelmann
Favorite
(P 319) CARDIOTOXICITY AND OVERALL SURVIVAL IN PATIENTS WITH SARCOMA TREATED WITH DOXORUBICIN, OLARATUMAB AND DEXRAZOXANE: A REAL-WORLD EXPERIENCE IN DENMARK
Bodil Elisabeth Engelmann
Favorite
Erbasi, Neslihan

Oregon Health & Science University
(P 93) INTERCALARY COMPRESSIVE OSSEOINTEGRATION OF DIAPHYSEAL TUMORS: A MULTI-INSTITUTIONAL CASE SERIES
Neslihan Erbasi
Favorite
Erdem, Zeynep

Leiden University Medical Center
(P 127) AN INTEGRATED CLINICAL GENOMIC AND TRANSCRIPTOMIC SUBGROUPING OF CENTRAL CHONDROSARCOMA
Zeynep Erdem
Favorite
ESCUDIE, Frederic

Institut Universitaire du Cancer de Toulouse
(P 12) DNA REPLICATION STRESS AND DEFICIENT HOMOLOGOUS RECOMBINATION IN OSTEOSARCOMA RISK AND THERAPY
Frederic ESCUDIE
Favorite
Espejo Freire, Andrea

University of Minnesota
(P 418) INTEGRATING SARCULATOR AND PET RESPONSE TO GUIDE NEOADJUVANT TREATMENT DECISIONS IN HIGH-RISK SOFT TISSUE SARCOMA
Andrea Espejo Freire
Favorite
Espinoza, Jossue

The University of Texas MD Anderson Cancer Center
(P 311) A FOLLOW-UP STUDY ON THE NOVEL USE OF CONTRAST-ENHANCED SUSCEPTIBILITY-WEIGHTED IMAGING FOR EXTREMITY DESMOID FIBROMATOSIS RESPONSE ASSESSMENT
Jossue Espinoza
Favorite
(P 317) BUILDING A PRE-SURGICAL MULTIPARAMETRIC-MRI-BASED PREDICTIVE TREATMENT RESPONSE MODEL FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA TO REPLACE RECIST
Jossue Espinoza
Favorite
(P 334) MRI VOLUMETRIC AND MODIFIED CHOI-BASED ASSESSMENT OF TREATMENT RESPONSE IN EXTREMITY DESMOID TUMORS TREATED WITH NIROGACESTAT OR SORAFENIB
Jossue Espinoza
Favorite
(P 406) PILOT STUDY: CAN A MULTIPARAMETRIC MRI-DERIVED MODEL OUTPERFORM RECIST PREDICTING PATHOLOGY RESPONSE IN RHABDOMYOSARCOMA?
Jossue Espinoza
Favorite
(P 420) THE EFFECT OF CHEMOTHERAPY AND RADIOTHERAPY IN THE MULTIPARAMETRIC MRI-BASED ASSESSMENT OF TREATMENT RESPONSE IN EXTREMITY SOFT-TISSUE UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Jossue Espinoza
Favorite
Esposito, Salvatore

Humanitas University
(P 339) POSTERIOR APPROACH FOR RADICAL RESECTION OF SACROCOCCYGEAL CHORDOMA: A SURGICAL PERSPECTIVE FROM A TERTIARY REFERRAL CENTER
Salvatore Esposito
Favorite
Eubank, Michael

Memorial Sloan Kettering Cancer Center
(P 409) RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS INCLUDING HLA GENOTYPE IN MYXOID LIPOSARCOMA
Michael Eubank
Favorite
Evans, Denisse

Life Raft Group
(P 190) TEMPORAL DECLINE IN PROGRESSION-FREE SURVIVAL, TIME ON MEDICATION, AND OVERALL SURVIVAL IN ADVANCED GASTROINTESTINAL STROMAL TUMOR
Denisse Evans
Favorite
Evans, Elizabeth

Adaptimmune
(P 247) SINGLE-CELL RNA SEQUENCING OF AFAMITRESGENE AUTOLEUCEL INDICATES MECHANISMS OF PERSISTENCE AND ANTI-TUMOR ACTIVITY
Elizabeth Evans
Favorite
Evans, Jeffry

Beatson West of Scotland Cancer Centre, University of Glasgow
(P 431) INVOKE: A PHASE 1 STUDY OF OKN4395, A FIRST-IN-CLASS EP2/EP4/DP1 TRIPLE PROSTANOID RECEPTOR ANTAGONIST, IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING SARCOMAS
Jeffry Evans
Favorite
Evans, Kathryn

Children's Cancer Institute Australia
(P 267) THE RAF/MEK INHIBITOR VS-6766 SHOWS EFFICACY IN RAS-MUTANT PEDIATRIC PRECLINICAL XENOGRAFT MODELS- A REPORT FROM THE PEDIATRIC PRECLINICAL IN VIVO TESTING CONSORTIUM
Kathryn Evans
Favorite
Evans, Mark

Caris Life Sciences
(P 154) BCOR-MUTATED CONVENTIONAL AND DEDIFFERENTIATED CHONDROSARCOMA: A CLINICOPATHOLOGIC STUDY
Mark Evans
Favorite
Evseev, Danyel

Arnie Charbonneau Cancer Institute and McCaig Institute for Bone and Joint Health
(P 238) INVESTIGATING HOW MACROPHAGES INFILTRATE THE TUMOUR MICROENVIRONMENT AND INFLUENCE THE EFFICACY OF CAR T THERAPY IN A MURINE MODEL OF STS
Danyel Evseev
Favorite
(P 378) HIGH DOSE RADIATION THERAPY PROMOTES IMMUNE SUPPRESSIVE MACROPHAGE PHENOTYPES, WHEREAS LOW DOSE RADIATION THERAPY PROMOTES IMMUNOGENIC MACROPHAGE PHENOTYPES IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Danyel Evseev
Favorite
Eward, William

Duke University
(P 19) SERUM EXOSOMES IDENTIFY AN ABERRANT PROTEOMIC SIGNATURE IN CANINE OSTEOSARCOMA PRECEDING METASTATIC PROGRESSION
William Eward
Favorite
(P 84) A MULTICENTER COMPARISON OF REVERSE TOTAL SHOULDER ARTHROPLASTY VERSUS HEMIARTHROPLASTY FOR ENDOPROSTHETIC RECONSTRUCTION FOLLOWING ONCOLOGIC RESECTION OF THE PROXIMAL HUMERUS
William Eward
Favorite
(P 119) DEVELOPMENT OF AN EXTINCTION THERAPY APPROACH FOR OSTEOSARCOMA USING ECO-EVOLUTIONARY PRINCIPLES
William Eward
Favorite
(P 214) FINANCIAL TOXICITY IN PATIENTS WITH A HISTORY OF EXTREMITY AND PELVIC SARCOMA TREATMENT
William Eward
Favorite
(P 259) PRECLINICAL MODELING OF CHEMOTHERAPY RELEASE IDENTIFIES MITOCHONDRIAL ADAPTATIONS IN DOXORUBICIN TREATED OSTEOSARCOMA
William Eward
Favorite
Exter, Ben

Cogent Biosciences
(P 425) BEZUCLASTINIB EXPANDED ACCESS PROGRAM (EAP) FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST)
Ben Exter
Favorite